Dengue vaccine: Local decisions, global consequences

Bulletin of the World Health Organization

Volumn 94, Issue 11, 2016, Pages 850-855

  López Gatell, Hugo ^a   Alpuche Aranda, Celia M ^a   Santos Preciado, José I ^b   Hernández Ávilaa, Mauricio ^a  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; VIRUS VACCINE;

AGE CLASS; BIOSAFETY; CHILD HEALTH; DENGUE FEVER; PUBLIC HEALTH; VACCINATION; VACCINE;

ARTICLE; CLINICAL TRIAL (TOPIC); DENGUE; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SENSITIVITY; HOSPITALIZATION; HUMAN; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PUBLIC HEALTH; RISK FACTOR; RISK MANAGEMENT; SEROTYPE; VACCINATION; DENGUE VIRUS; DEVELOPING COUNTRY; DRUG EFFECTS; FEMALE; MALE; PRESCHOOL CHILD; SAFETY; TREATMENT OUTCOME;

CHILD, PRESCHOOL; DENGUE; DENGUE VIRUS; DEVELOPING COUNTRIES; FEMALE; HUMANS; MALE; SAFETY; TREATMENT OUTCOME; VIRAL VACCINES;

EID: 84994591264     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.15.168765     Document Type: Article

References (30)

1. Guzmán MG, Harris E. Dengue. Lancet. 2015 Jan 31;385(9966): 453-65. doi: http://dx.doi.org/10.1016/S0140-6736(14)60572-9 PMID: 25230594
2. Lopez-Gatell H, Hernandez-Avila M, Hernandez JE, Alpuche-Aranda CM. Dengue in Latin America: a persistent and growing public health challenge. In: Neglected tropical diseases-Latin America and the Caribbean. Vienna: Springer; 2015. pp. 203-24. doi: http://dx.doi.org/10.1007/978-3-7091-1422-3_11
3. Sanofi Pasteur dengue vaccine approved in Costa Rica. Lyon: Sanofi Pasteur; 2016. Available from: http://www.sanofipasteur.ca/node/49001 [cited 2016 Jun 21].
4. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2016-conclusions and recommendations. Wkly Epidemiol Rec. 2016 May 27;91(21): 266-84. PMID: 27236869
5. Background paper on dengue vaccines. Geneva: Strategic Advisory Group of Experts Working Group on Dengue Vaccines; 2016. Available from: http://www.who.int/immunization/sage/meetings/2016/april/1_Background_Paper_Dengue_Vaccines_2016_03_17.pdf [cited 2016 Aug 16].
6. Capeding MR, Tran NH, Hadinegoro SRS, Ismail HI, Chotpitayasunondh T, Chua MN, et al.; CYD14 Study Group. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014 Oct 11;384(9951): 1358-65. doi: http://dx.doi.org/10.1016/S0140-6736(14)61060-6 PMID: 25018116
7. Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, et al.; CYD15 Study Group. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015 Jan 8;372(2): 113-23. doi: http://dx.doi.org/10.1056/NEJMoa1411037 PMID: 25365753
8. Hadinegoro SRS, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al.; CYD-TDV Dengue Vaccine Working Group. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015 Sep 24; 373(13): 1195-206. doi: http://dx.doi.org/10.1056/NEJMoa1506223 PMID: 26214039
9. Flasche S, Jit M, Rodriguez-Barraquer I, Coudeville L, Recker M, Koelle K et al. Comparative modelling of dengue vaccine public health impact (CMDVI). Geneva: World Health Organization; 2016. Available from: http://www.who.int/immunization/sage/meetings/2016/april/2_CMDVI_Report_FINAL.pdf [cited 2016 May 20].
10. Simmons CP. A candidate dengue vaccine walks a tightrope. N Engl J Med. 2015 Sep 24;373(13): 1263-4. doi: http://dx.doi.org/10.1056/NEJMe1509442 PMID: 26214040
11. Hernández-Ávila M, Santos-Preciado JI. Análisis de la evidencia sobre eficacia y seguridad de la vacuna de dengue CYD-TDV y su potencial registro e implementación en el Programa de Vacunación Universal de México. Salud Publica Mex. 2016 Jan-Feb; 58(1): 71-83. Spanish. doi: http://dx.doi.org/10.21149/spm.v58i1.7670 PMID: 26879510
12. Halstead SB, Russell PK. Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine. 2016 Mar 29;34(14): 1643-7. doi: http://dx.doi.org/10.1016/j.vaccine.2016.02.004 PMID: 26873054
13. Endy TP. Human immune responses to dengue virus infection: lessons learned from prospective cohort studies. Front Immunol. 2014 04 24; 5: 183-183. doi: http://dx.doi.org/10.3389/fimmu.2014.00183 PMID: 24795725
14. Global Advisory Committee on Vaccine Safety. Addendum to report of the Global Advisory Committee on Vaccine Safety (GACVS), 10-11 June 2015. Safety of CYD-TDV dengue vaccine. Wkly Epidemiol Rec. 2015 Aug 21; 90(34): 421-3. PMID: 26298882
15. Guzmán MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol. 2013 Jul; 158(7): 1445-59. doi: http://dx.doi.org/10.1007/s00705-013-1645-3 PMID: 23471635
16. Wilder-Smith A. Dengue vaccines: dawning at last? Lancet. 2014 Oct 11; 384(9951): 1327-9. doi: http://dx.doi.org/10.1016/S0140-6736(14)61142-9 PMID: 25018119
17. Thomas SJ. Preventing dengue-is the possibility now a reality? N Engl J Med. 2015 Jan 8; 372(2): 172-3. doi: http://dx.doi.org/10.1056/NEJMe1413146 PMID: 25365706
18. Guy B, Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol. 2016 Jan; 14(1): 45-54. doi: http://dx.doi.org/10.1038/nrmicro.2015.2 PMID: 26639777
19. Lim JK, Lee Y-S, Wilder-Smith A, Thiry G, Mahoney R, Yoon IK. Points for consideration for dengue vaccine introduction-recommendations by the Dengue Vaccine Initiative. Expert Rev Vaccines. 2016 Apr; 15(4): 529-38. doi: http://dx.doi.org/10.1586/14760584.2016.1129279 PMID: 26651238
20. Global vaccine safety blueprint. Geneva: World Health Organization; 2012. Available from: http://extranet.who.int/iris/restricted/bitstream/10665/70919/1/WHO_IVB_12.07_eng.pdf?ua=1 [cited 2016 Aug 16].
21. Bentsi-Enchill AD, Schmitz J, Edelman R, Durbin A, Roehrig JT, Smith PG, et al.; Live Dengue Vaccines Technical Consultation Reporting Group. Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation. Vaccine. 2013 May 28; 31(23): 2603-9. doi: http://dx.doi.org/10.1016/j.vaccine.2013.03.038 PMID: 23570986
22. Technical Advisory Group on Vaccine-Preventable Diseases. Final report of the XXIII Technical Advisory Group (TAG) Meeting on Vaccine-preventable Diseases of the Pan American Health Organization, Varadero, Cuba, 1-3 July 2015. Washington: Pan American Health Organization; 2015. Available from: http://www.who.int/immunization/sage/meetings/2015/october/5_AMR_2015_TAG_Report_ENG_Final.pdf [cited 2016 May 20].
23. Djulbegovic B, Paul A. From efficacy to effectiveness in the face of uncertainty: indication creep and prevention creep. JAMA. 2011 May 18; 305(19): 2005-6. doi: http://dx.doi.org/10.1001/jama.2011.650 PMID: 21586716
24. Rodriguez-Barraquer I, Mier-y-Teran-Romero L, Ferguson N, Burke DS, Cummings DA. Differential efficacy of dengue vaccine by immune status. Lancet. 2015 May 2; 385(9979):1726. doi: http://dx.doi.org/10.1016/S0140-6736(15)60889-3 PMID: 25943936
25. Russell PK, Halstead SB. Challenges to the design of clinical trials for live-attenuated tetravalent dengue vaccines. PLoS Negl Trop Dis. 2016 08 11; 10(8):e0004854. doi: http://dx.doi.org/10.1371/journal.pntd.0004854 PMID: 27513928
26. Evaluación internacional del programa de vacunación universal de México. Mexico City: Pan American Health Organization; 2015. Spanish.
27. Global strategy for dengue prevention and control 2012-2020. Geneva: World Health Organization; 2013.
28. Dellepiane N, Wood D. Twenty-five years of the WHO vaccines prequalification programme (1987-2012): lessons learned and future perspectives. Vaccine. 2015 Jan 1; 33(1): 52-61. doi: http://dx.doi.org/10.1016/j.vaccine.2013.11.066 PMID: 24300593
29. Global vaccine safety initiative portfolio activities 2012-2020. Geneva: World Health Organization; 2015.
30. Thompson A, Komparic A, Smith MJ. Ethical considerations in post-market-approval monitoring and regulation of vaccines. Vaccine. 2014 Dec 12; 32(52): 7171-4. doi: http://dx.doi.org/10.1016/j.vaccine.2014.10.016 PMID: 25454882